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Abstract
Background: Optimal timing for the start of vasopressors (VP) in septic shock has not been widely studied since it
is assumed that fluids must be administered in advance. We sought to evaluate whether a very early start of VP,
even without completing the initial fluid loading, might impact clinical outcomes in septic shock.
Methods: A total of 337 patients with sepsis requiring VP support for at least 6 h were initially selected from a
prospectively collected database in a 90-bed mixed-ICU during a 24-month period. They were classified into very-
early (VE-VPs) or delayed vasopressor start (D-VPs) categories according to whether norepinephrine was initiated or
not within/before the next hour of the first resuscitative fluid load. Then, VE-VPs (n = 93) patients were 1:1 propensity
matched to D-VPs (n = 93) based on age; source of admission (emergency room, general wards, intensive care unit);
chronic and acute comorbidities; and lactate, heart rate, systolic, and diastolic pressure at vasopressor start. A risk-
adjusted Cox proportional hazard model was fitted to assess the association between VE-VPs and day 28 mortality.
Finally, a sensitivity analysis was performed also including those patients requiring VP support for less than 6 h.
Results: Patients subjected to VE-VPs received significantly less resuscitation fluids at vasopressor starting (0[0–510] vs.
1500[650–2300] mL, p < 0.001) and during the first 8 h of resuscitation (1100[500–1900] vs. 2600[1600–3800] mL, p <
0.001), with no significant increase in acute renal failure and/or renal replacement therapy requirements. VE-VPs was
related with significant lower net fluid balances 8 and 24 h after VPs. VE-VPs was also associated with a significant
reduction in the risk of death compared to D-VPs (HR 0.31, CI95% 0.17–0.57, p < 0.001) at day 28. Such association was
maintained after including patients receiving vasopressors for < 6 h.
Conclusion: A very early start of vasopressor support seems to be safe, might limit the amount of fluids to resuscitate
septic shock, and could lead to better clinical outcomes.
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Background
Early detection and prompt reversion of sepsis-induced
tissue hypoperfusion are key elements in the treatment of
patients with septic shock [1, 2]. Fluid administration is
widely accepted as the first-line therapy followed by
vasopressor use in persistently hypotensive patients or in
those in whom arterial pressure is judged to be insufficient
to ensure an adequate tissue perfusion [2]. Studies on
implementation of therapeutic bundles in sepsis [3, 4] and
recent randomized controlled trials on early goal-directed
therapy in septic shock [5–7] highlighted the importance
of the initial fluid loading and turned this into a standard
for the clinical practice. Indeed, current guidelines on
sepsis management emphasize on the administration of at
least 30mL/kg of IV crystalloids within the first 3 h of
identification of sepsis-induced hypoperfusion, but a
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recommendation on the timing to start vasopressor support
was not clearly stated [1]. Nevertheless, a recent update on
the last recommendations of Surviving Sepsis Campaign
claims for an immediate start of resuscitation and treatment
in a “1-h bundle” [8] including the use of vasopressors in
the case of life-threatening hypotension, during or after
fluid resuscitation to maintain a MAP ≥ 65mmHg.
Although this initiative embraces the concept of sepsis as a
medical emergency, the level of evidence for these re-
commendations [8] is quite limited and remains debatable.
Recent studies have questioned the clinical benefit of
fluid boluses in patients with sepsis and hypotension [9,
10]. In line with this, recent experimental data suggested
that fluid resuscitation preceding the start of vasopres-
sors is associated with higher lactate levels and a para-
doxical increase in vasopressor requirements when
compared with an immediate start of vasopressor ther-
apy without previous fluid administration [11]. Likewise,
a number of observational studies suggest that the
volume of resuscitation fluids and net fluid balance is as-
sociated with mortality in sepsis [12–24]. Nevertheless,
other data indicates that vasopressors should be admin-
istered in combination with fluids since isolated vaso-
pressors can improve arterial pressure but not regional
blood flow [25].
An early start of vasopressor therapy may have sev-
eral beneficial effects. First, norepinephrine may in-
crease cardiac output by increasing stressed volume
[26], by improving myocardial contractility [27], and
through other various mechanisms [28]. Second, nor-
epinephrine might increase microcirculatory perfusion
in septic shock [29–31], especially when the baseline
microcirculatory blood flow is abnormal [32]. Third,
early use of norepinephrine may improve the regional
distribution of blood flow and prevent fluid overload
[25]. Finally, delays in correcting hypotension are as-
sociated with increased risk of death in septic patients
[33–35], whereby prompt correction of hypotension
might influence clinical outcomes. Indeed, a recent
phase II randomized controlled trial suggested that
early use of norepinephrine might improve the possi-
bility to achieve more sustained mean arterial pres-
sure levels and adequate tissue perfusion parameters
[36]. However, this trial was limited by a specificity of
the protocol requesting administration of a fixed dose
of vasopressors in the early group, which is not the
usual way of administering vasopressors.
Since the optimal timing of the introduction of vaso-
pressors remains unknown and whether the benefits or
harm of vasopressor introduction even preceding fluid
resuscitation has not been still answered, we evaluated
the impact of very early and the concurrent start of
vasopressor support and fluid resuscitation on clinical
outcomes in patients with septic shock.
Methods
Study population
Adult patients > 18 years or older fulfilling the diagnostic
criteria for septic shock stated in the Surviving Sepsis
Campaign: International Guidelines for Management of
Severe Sepsis and Septic Shock: 2012 [37] and based on
the previous 2001 SCCM/ESICM/ACCP/ATS/SIS Inter-
national Sepsis Definitions Conference [38] were pro-
spectively collected between January 2015 and February
2017 in one mixed-ICU in a university hospital in
Colombia (Fundación Valle del Lili, Cali, Colombia).
This original definition was maintained as inclusion cri-
teria since it was valid during the period in which the
database was constructed. The ethical and research com-
mittee involving human beings approved the use of the
data (Protocol number 1238, IRB/EC approval number
099-2018, Fundación Valle del Lili, Cali, Colombia). The
presence of infection was determined according to the
Centers for Diseases Control and Prevention criteria
[39]. For analysis purposes, however, septic shock was
re-classified according to the current Third International
Consensus Definitions for Sepsis and Septic Shock (Sepsis
3.0), which consider the presence of suspected infection
accompanying organ dysfunction, the use of vasopres-
sors, MAP < 65 mmHg, and lactate levels > 2mmol/L
[40]. Meanwhile, patients with sepsis and vasopressor re-
quirement but without hyperlactatemia were re-
classified and analyzed as sepsis-related acute circulatory
failure. Surviving patients requiring less than 6 h of vaso-
pressor support were not included in the initial main
analysis, as they could not be representative of septic
shock. Nevertheless, these patients were also evaluated
in an ulterior sensitivity analysis. Patients < 18 years old,
pregnant women, patients with liver failure (prothrom-
bin time > 15 s or international normalized ratio ≥ 1.5
and any hepatic encephalopathy), advanced liver cirrho-
sis (Child-Pugh C), and those with do-not-resuscitate
orders were excluded.
Study design
Very early start of vasopressor (VE-VPs) was defined as
that vasopressor support initiated within the next hour or
even before the first fluid load with resuscitative intention
(FRLoad). Those patients in whom vasopressor support
was started > 1 h after the FRLoad were classified as de-
layed VPs (D-VPs). In each case, the start of vasopressor
(VPs) was identified and used as a reference point to deter-
mine the time elapsed from the first hypotension episode
(FHypo) and from the FRLoad. The decision to start vaso-
pressor support was always taken by the attending phys-
ician according to his clinical judgment. The delay time
until the start of antibiotics was also recorded with respect
to the first hypotension episode. In addition, time intervals
from FHypo, FRLoad, and VPs up to ICU admission were
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also recorded. The volume of resuscitation fluids received
before VPs was also registered. Then, the volume of resus-
citation fluids and dose of vasopressors were recorded at
2-h intervals from the VPs up to 8 h, and then, 12, 18, and
24 h after VPs. Net fluid balance was also recorded at
FHypo, FRLoad, VPs, and also 8 h (8H) and 24 h (24H)
after the start of vasopressor support.
General demographics including age, APACHE II, co-
morbidities, and origin of the patient (emergency room,
general ward, or intensive care unit) were registered.
Heart rate and arterial pressure were also recorded at
FHypo, FRLoad, VPs, and at 2, 4, 6, 8, and 24 h after the
VPs. Multiple organ dysfunction was assessed using the
Sequential Organ Failure Assessment Score (SOFA) [41].
Ventilator-free days, requirement of renal replacement
therapy (RRT), and RRT-free days were also calculated.
Finally, ICU and hospital length of stay were recorded
along with UCI, in-hospital, and 28 days of mortality.
General management
Patients followed an early quantitative resuscitation proto-
col aiming to target: (a) MAP ≥ 65mmHg; (b) urine output
> 0.5mL/kg/min; (c) ScvO2 ≥ 70%, when available; and (d)
normalization of lactate levels or decreasing of 20% each
2 h in lactate levels. Fluid resuscitation was performed ad-
ministering repeated fluid challenges with crystalloids and/
or albumin 4%, using the central venous pressure (CVP) as
a dynamic safety limit during fluid loads in patients with a
central line in place. Hydroxyethyl starches (HES) were not
used. The usual protocol in our institution includes the use
of pulse pressure and stroke volume variations to guide
fluid resuscitation (when usable). Additionally, echocardio-
graphic determination of velocity-time integral (VTI) be-
fore and after passive leg raising (PLR), and end-expiratory
occlusion maneuvers were used whenever applicable. The
clinical assessment of peripheral perfusion (e.g., measuring
capillary refill time [42] and/or the evaluation of mottling
score [43]) and the use of advanced monitoring of cardiac
output were allowed at the discretion of the attending
physician. Norepinephrine was the first-choice vasopressor
used to achieve MAP ≥ 65, while vasopressin titrated up to
0.04 UI/min was also allowed to increase MAP or to de-
crease norepinephrine dose, but never as a single vasopres-
sor. Dobutamine up to 20 μcg/kg min was used in case of
myocardial dysfunction, when ScvO2 or lactate goals were
not achieved or when clinical signs of hypoperfusion per-
sisted despite adequate fluid resuscitation. Mechanical ven-
tilation was used when indicated, providing light sedation
(midazolam or propofol) and analgesia (fentanyl). Red
blood cell transfusion was used to maintain hemoglobin
levels at or above 7.0 g/dl or > 10.0 g/dl in case of cardiac
ischemia. Low-dose hydrocortisone was used when the
vasopressor requirement did not decrease during the first
6 h of resuscitation in the presence of an adequate
intravascular volume. Glycemic control was adjusted to
maintain glucose levels < 150mg/dL, while thrombosis
prophylaxis and stress ulcer protection were also provided
according to international guidelines valid at the time in
which patients were treated [37].
Statistical analysis
Patients meeting eligibility criteria and subjected to VE-
VPs were propensity-matched with those subjected to D-
VPs. For that, factors potentially influencing the decision of
very early vasopressor support such as source of admission
(emergency room, intensive care unit), age, chronic, and
acute comorbidities (hypertension, coronary disease,
chronic heart failure, end-stage renal failure, chronic atrial
fibrillation, chronic use of steroids, previous stroke,
diabetes, cancer, chronic obstructive pulmonary disease,
cirrhosis Child-Pugh C, acute myocardial infarction, acute
heart failure, acute stroke, acute atrial fibrillation), diastolic
blood pressure, systolic blood pressure and heart rate at
the VPs, the heart rate/diastolic blood pressure ratio at the
FRLoad, and arterial lactate levels at the VPs were included
in a logistical model to estimate the propensity scores.
After fitting the propensity score, a nearest neighbor-
matching algorithm extracted 1:1 matched pairs of VE-VPs
and D-VPs individuals. The effect of early start of vasopres-
sors on mortality at day 28 was assessed using a Cox-
proportional hazards model adjusted by SOFA score at day
1, the presence of hyperlactatemia (septic shock according
to Sepsis 3.0 definition), delay time of antibiotic administra-
tion, and the net fluid balance at 24 h. In addition, adjunct-
ive therapies (e.g., renal replacement therapies, vasopressin,
and steroid use) were also used as covariables. A condi-
tional forward stepwise technique was used after verifying
all subsets selection, while the proportional hazards as-
sumption was tested on the basis of Schoenfeld residuals.
Repeated measures ANOVA were used to evaluate the
time-course of vasopressor dose and cumulated resusci-
tation fluids during the first 8 h of resuscitation and the
inter-group differences between VE-VPs and D-VPs.
Supplementary sensitivity analysis was conducted to
evaluate the relationship between VE-VPs and mortality
at day 28. For this, those patients receiving vasopressor
support for less than 6 h were included to construct a
new propensity-matching algorithm followed by a new
Cox-proportional hazards model adjusted by the same
covariables. Continuous variables were compared using
non-parametric test and data are presented as medians
(25th–75th percentiles). A p < 0.05 was considered statis-
tically significant.
Results
From 646 patients screened, 337 patients were finally in-
cluded in the study (Additional file 1: Figure S1). For the
analysis, 239 were re-classified as septic shock (Sepsis
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3.0 definition), while 98 were re-classified as a sepsis-
related acute circulatory failure. The mortality of the
entire cohort at 28 days was 38.3%, while the length of
ICU and hospital stay were 9 [4–16] and 14 [6–29] days,
respectively. A STROBE statement checklist for observa-
tional studies is provided in Additional file 1: Table S1.
Vasopressor support was initiated before or within the
next hour of the first fluid resuscitation load (VE-VPs
group) in 93 patients, while in the remaining 244, it was
started > 1 h after the FRLoad (D-VPs group). General
characteristics of the pre-matched groups are presented
in Additional file 1: Table S2. Patients in the pre-
matched D-VPs group had lower diastolic and mean ar-
terial blood pressures at VPs, and they also had slightly
higher heart rate to diastolic pressure ratios at the time
of norepinephrine administration (Additional file 1:
Table S2). Nevertheless, after the 1:1 propensity match-
ing, VE-VPs (n = 93) and D-VP (n = 93) groups were
adequately balanced (Table 1). Time elapsed between
the first hypotension episode and the start of VP support
(FHypo-to-VPs interval) was significantly longer in the
D-VPs group. However, there were no significant differ-
ences in the time from VPs, FRLoad, and FHypo up to
ICU admission (Table 1). There were also no significant
differences in the time-course of mean arterial pressure
after the start of vasopressor support (Additional file 1:
Figure S2).
The volume of resuscitation fluids in the pre-vasopressor
period (i.e., the FRLoad-to-VPs interval) was significantly
lower in the VE-VPs (Table 1). Similarly, patients in the
VE-VPs received less resuscitation fluids into the first 8 h of
resuscitation (repeated measures ANOVA, inter-group dif-
ference, p < 0.001; time*group interaction, p = 0.04) repre-
sented by lower volumes at the start of vasopressors and
less steep increases in cumulated resuscitation fluids at the
end of such resuscitation period (Fig. 1, Table 1). Mean-
while, the net fluid balance at VPs, 8 and 24 h, was signifi-
cantly higher in the D-VPs group (repeated measures
ANOVA, inter-group difference, p < 0.001; time*group
interaction, p < 0.001) (Additional file 1: Figure S3).
There were no significant differences between VE-VPs
and D-VPs groups regarding the maximal dose of nor-
epinephrine, steroids and vasopressin use, or requirement
of RRT (Table 1). Similarly, the time-course of norepin-
ephrine doses, heart rate to diastolic pressure ratio, and
pulse pressure was not significantly different between
groups (Additional file 1: Figures S4, S5, S6). No cases of
severe digital or severe vasopressor-induced splanchnic
ischemia were documented.
The Cox-proportional hazard model revealed a signifi-
cant decreased risk of death at day 28 for VE-VPs (HR
0.31, CI95% 0.17–0.57, p < 0.001) (Fig. 2, Table 2). The
beneficial effect of VE-VPs remained in patients fulfilling
the septic shock criteria according to the Sepsis 3.0
definition (HR 0.40; 95% CI, 0.21–0.74; p = 0.004) (Add-
itional file 1: Figure S7a). Information about the Cox-
proportional hazard models in the non-matched population
is provided in Additional file 1: Table S3.
A sensitivity analysis including patients that used vaso-
pressor support for < 6 h also demonstrated that VE-VPs
is related with a significant lower risk of death at day 28
(HR 0.47, CI95% 0.26–0.85, p = < 0.013) (Additional file 1:
Table S4).
Discussion
Two key points can be extracted from our observations: (a)
a very early start of vasopressor support is associated with
less use of resuscitation fluids, less fluid accumulation, and
possibly, shortening of hypotension time; (b) very early start
of vasopressors was not associated with increased kidney
injury or ischemia-related adverse effects; but rather, it
might decrease mortality in patients with septic shock.
Resuscitation of septic shock is currently based on fluid
administration as first-line therapy followed by vasopres-
sor support when the patient is supposed to become non-
fluid responsive. Although widely accepted, this practice is
not clearly supported by the evidence. In fact, information
about the “pre-vasopressor” period in septic shock is quite
limited because most of the current evidence on early
goal-directed resuscitation comes from randomized con-
trolled trials in which patients received a pre-determined
amount of fluids as a prerequisite to be included (5–7).
We retrospectively studied this “pre-vasopressor” phase in
patients with sepsis requiring VP support for at least 6 h,
followed by a sensitivity analysis including a minority
using VP support for less than 6 h. Those in which VP
was started < 1 h from the first fluid load (VE-VPs) re-
ceived significantly less amount of resuscitation fluids at
both pre-vasopressor and early resuscitation period, the
net fluid accumulation at 8 and 24 h was significantly
lower and they also had a significant lower mortality.
Observational studies and post hoc analysis of previous
clinical trials suggest that greater accumulation of fluids
is related with worse clinical outcomes [12, 18, 44],
which agree with our results. Such effect of VE-VPs on
the lower net fluid accumulation in our study was appar-
ently mediated by the limiting fluid administration more
than by increased fluid elimination. Although the lower
mortality of patients in which norepinephrine was preco-
ciously initiated might have several potential explana-
tions, a more rapid restoration of blood flow in
combination with lower fluid accumulation could early
restitute tissue perfusion and avoid the harm mediated
by fluid overload. Interestingly, VE-VPs patients had the
same blood pressure at time of first fluid bolus as
patients with D-VPs, suggesting that the differences be-
tween groups were related to the timing of vasopressor
initiation more than to the severity of hypotension.
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Table 1 General characteristics, hemodynamics, perfusion parameters, fluids, vasopressors, and outcomes for the propensity-
matched cohort
All Very early-VPs (n = 93) Delayed-VPs (n = 93) p
General characteristics
Age, years 64 (52–74) 63 (51–74) 65 (53–75) 0.55
Male sex, n (%)
Weight, kg 69 (58–77) 70 (57–80) 65 (59–72) 0.08
APACHE II 16 (13–21) 16 (13–19) 16 (13–23) 0.22
SOFA day 1 9 (7–12) 9 (8–12) 10 (7–12) 0.93
Infection source, n (%)
Lung 60 (32.4) 33 (35.9) 27 (29.0) 0.35
Genitourinary 33 (17.7) 17 (18.3) 16 (17.2) 1.00
Abdominal 64 (34.4) 29 (31.2) 35 (37.6) 0.44
Soft tissue 17 (9.1) 9 (9.7) 8 (8.6) 1.00
Bacteremia 39 (21.0) 17 (18.3) 22 (23.7) 0.47
Other 11 (5.9) 7 (7.5) 4 (4.3) 0.54
Origin 0.56
Emergency room 135 (72.6) 66 (71.0) 69 (74.2)
General ward 24 (12.9) 11 (11.8) 13 (14.0)
Intensive care unit 27 (14.5) 16 (17.2) 11 (11.8)
Comorbidities, n (%)
Hypertension 73 (39.2) 34 (36.6) 39 (41.9) 0.55
Coronary disease 9 (4.8) 4 (4.3) 5 (5.4) 1.00
Chronic heart failure 15 (8.1) 7 (7.5) 8 (8.6) 1.00
ESRF 12 (6.5) 5 (5.4) 7 (7.5) 0.77
Previous stroke 3 (1.6) 3 (3.2) 0 (0.0) 0.25
Chronic atrial fibrillation 12 (6.5) 12 (6.5) 12 (6.5) 1.00
Diabetes 36 (19.4) 18 (19.4) 18 (19.4) 1.00
Cancer 38 (20.4) 21 (22.6) 17 (18.3) 0.59
COPD 20 (10.8) 14 (15.1) 6 (6.5) 0.10
Chronic use steroids 28 (15.1) 9 (9.7) 19 (20.4) 0.06
Cirrhosis 12 (6.5) 4 (4.3) 8 (8.6) 0.16
Acute myocardial infarction 3 (1.6) 2 (2.2) 1 (1.1) 1.00
Acute heart failure 12 (6.5) 8 (8.6) 4 (4.3) 0.37
Acute stroke 6 (3.2) 2 (2.2) 4 (4.3) 0.68
Acute atrial fibrillation 9 (4.8) 2 (2.2) 7 (7.5) 0.17
Septic shock definition 0.19
Sepsis + VP + hyperlactatemia, n (%) 127 (68.3) 64 (68.8) 63 (67.7)
Sepsis + VP, n (%) 59 (31.7) 29 (31.2) 30 (32.3)
Supportive/rescue therapies
Steroid use, n (%) 114 (61.3) 57 (61.3) 57 (61.3) 1.00
Vasopressin use, n (%) 63 (33.9) 29 (31.2) 34 (36.6) 0.54
Acute RRT 35 (27.6) 18 (28.1) 17 (27.0) 0.50
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Table 1 General characteristics, hemodynamics, perfusion parameters, fluids, vasopressors, and outcomes for the propensity-
matched cohort (Continued)
All Very early-VPs (n = 93) Delayed-VPs (n = 93) p
Time intervals
Up to VPs
From first hypotension to VPs 2 (0–4) 1 (0–2) 3 (2–5) < 0.001
From FRLoad to VPs 0 (0–3) 0 (0–1) 3 (1–4) < 0.001
Up to ICU admission
From VPs to ICU admission 2 (0–4) 1 (0–3) 1 (0–4) 0.87
From first hypotension to ICU admission 3 (1–4) 3 (1–4) 3 (2–4) 0.91
From FRLoad to ICU admission 2 (0–4) 2 (1–3) 2 (1–3) 0.78
Up to antibiotic start
From first hypotension to antibiotics 2 (0–5) 3 (1–5) 1 (−3–5) 0.04
Hemodynamics, perfusion parameters
At FRLoad
SAP 88 (78–98) 89 (79–100) 88 (77–97) 0.61
DAP 47 (40–55) 47 (41–55) 47 (40–54) 0.90
MAP 59 (54–65) 59 (54–67) 60 (55–66) 0.74
HR 105 (90–118) 103 (90–118) 106 (90–118) 0.73
PP 40 (30–53) 41 (31–54) 40 (30–50) 0.73
DSI 2.26 (1.84–2.68) 2.13 (1.81–2.56) 2.12 (1.80–2.56) 0.91
At VPs
SAP 89 (82–102) 92 (83–102) 88 (82–100) 0.22
DAP 48 (42–55) 48 (41–54) 48 (42–55) 0.85
MAP 57 (55–66) 57 (56–59) 57 (55–59) 0.57
HR 102 (87–118) 100 (87–118) 104 (89–117) 0.73
PP 41 (32–53) 43 (31–55) 41 (34–50) 0.56
DSI 2.17 (1.71–2.56) 2.17 (1.70–2.62) 2.17 (1.75–2.60) 0.83
pH arterial 7.33 (7.26–7.39) 7.32 (7.25–7.39) 7.34 (7.26–7.39) 0.50
BE arterial − 8.0 (− 11.9 to − 4.1) − 7.8 (− 11.4 to − 3.9) − 8.2 (−12.0 to − 4.2) 0.43
SvO2, %, n 71.5 (64.5–79.5), 96 72.2 (62.8–80.5), 46 71.5 (68.0–78.5), 50 0.67
Pv-aCO2, mmHg, n 4.4 (3.5–6.4), 95 4.8 (3.8–6.1), 46 4.1 (3.5–6.4), 49 0.69
PvaCO2/Da-vO2 ratio, n 1.41 (1.01–1.98), 79 1.44 (1.01–1.93), 41 1.38 (1.02–2.14), 39 0.87
Lactate initial, mmol/L, n 2.4 (1.5–4.5), 186 2.4 (1.6–4.2), 93 2.6 (1.3–4.6), 93 0.84
Lactate 6H, mmol/L 2.0 (1.1–3.8), 186 1.9 (1.1–3.2), 93 2.1 (1.1–4.0), 93 0.55
Lactate 24H, mmol/L, n 1.7 (1.1–3.2), 158 1.6 (1.0–2.7), 80 1.9 (1.1–4.5), 78 0.04
CVP at VP, mmHg, n 7 (5–12), 29 11 (7–13), 11 6 (4–9), 18 0.09
CVP at 6H, mmHg, n 8 (5–12), 82 7 (5–12), 40 8 (5–12), 42 0.98
CVP at 24H, mmHg, n 8 (6–13), 107 8 (6–12), 52 10 (6–15), 55 0.28
Fluids/VP/inotropics
Cumulated volume of resuscitation fluids, mL
FRLoad to VPs 590 (0–1565) 0 (0–500) 1500 (650–2300) < 0.001
VPs to 2H 1000 (450–1900) 500 (200–1100) 1700 (1000–2700) < 0.001
VPs to 4H 1230 (500–2350) 700 (300–1500) 1800 (1000–2880) < 0.001
VPs to 6H 1500 (750–2500) 900 (500–1500) 2000 (1400–3100) < 0.001
VPs to 8H 1750 (900–3000) 1100 (500–1900) 2600 (1600–3800) < 0.001
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All patients included in our study followed a quantita-
tive resuscitation protocol in which fluid responsiveness
was repeatedly tested during the initial resuscitation
period aiming to achieve some tissue perfusion goals.
Remarkably, although receiving lower amount of resusci-
tation fluids for achieving the same resuscitation goals,
patients in the VE-VPs group had a significantly lower
mortality, which is in line with studies showing that nor-
epinephrine may reduce preload dependency [45] due to
recruitment of preload reserve from the unstressed
blood volume, thus leading to lower fluid requirement.
Unfortunately, although biologically plausible, the obser-
vational nature of our study does not allow confirming
whether a more precocious mobilization from non-
stressed to stressed blood volume by early introduction
of vasopressors might have influenced the requirement
of resuscitation fluids.
A previous observational study suggested that delayed
introduction of VP support after initial fluid loading [46]
might be related with worse clinical outcomes. In addition
to a longer time of pre-vasopressor hypotension, the de-
layed vasopressor group was subjected to a more severe
hypotension even after the introduction of the vasopressor
support itself, which hinders the actual effect of the timing
of vasopressor use [46]. In contrast, in our study,
hypotension was rapidly corrected in both VE-VPs and D-
VPs groups, and the time-course of mean arterial pressure
was quite similar between them, at least after vasopressor
introduction. Nevertheless, time elapsed between the first
hypotension episode and the introduction of VP support
was significantly shortened in the VE-VPs, which is in line
with studies suggesting that shorter hypotension times are
associated with better outcomes in septic shock [33, 34].
Unfortunately, we recorded blood pressure at discrete
Table 1 General characteristics, hemodynamics, perfusion parameters, fluids, vasopressors, and outcomes for the propensity-
matched cohort (Continued)
All Very early-VPs (n = 93) Delayed-VPs (n = 93) p
Cumulated volume of resuscitation fluids, mL/kg
FRLoad to VPs 8.8 (0.0–25.0) 0.0 (0.0–8.8) 21.9 (9.0–37.0) < 0.001
VPs to 2H 16.0 (6.3–30.0) 7.3 (3.2–17.8) 25.0 (15.1–41.8) < 0.001
VPs to 4H 18.7 (8.1–33.3) 10.0 (4.3–21.6) 28.3 (17.1–45.4) < 0.001
VPs to 6H 23.1 (10.0–38.5) 12.5 (6.9–24.1) 28.6 (21.9–50.0) < 0.001
VPs to 8H 25.9 (12.5–44.5) 16.7 (8.6–27.3) 42.5 (24.3–58.1) < 0.001
Delta of resuscitation fluids, mL
VPs to 2H 175 (0–500) 200 (0–500) 0 (0–400) 0.16
2H to 4H 0 (0–300) 0 (0–400) 0 (0–300) 0.92
4H to 6H 0 (0–370) 0 (0–300) 0 (0–400) 0.11
6H to 8H 0 (0–500) 0 (0–300) 300 (0–630) < 0.001
Net fluid balance
At FRLoad 552 (0–2507) 310 (0–1750) 340 (0–2500) 0.19
At VPs 1989 (661–3700) 760 (10–2300) 2090 (920–3260) < 0.001
At 6H 2594 (1469–5055) 1760 (1070–3410) 2680 (1470–4480) < 0.001
At 24H 4762 (3197–7049) 3905 (2370–5100) 5400 (3790–7290) < 0.001
Norepinephrine max. dose, μg/kg/min 0.26 (0.13–0.48) 0.26 (0.11–0.45) 0.28 (0.15–0.53) 0.32
Dobutamine max. dose, μg/kg/min, n 5.2 (3.0–10.2), 28 5.0 (3.7–7.0), 13 6.6 (3.0–11.6), 15 0.55
Clinical outcomes
LOS-ICU 9 (5–17) 9 (5–18) 8 (4–17) 0.30
LOS-Hospital 16 (7–32) 17 (9–32) 15 (6–30) 0.11
Mechanical ventilation-free days 22 (0–28) 23 (14–28) 21 (0–26) 0.03
RRT-free days 6 (0–18) 8 (1–18) 1 (0–13) 0.26
Mortality of 28 days, n (%) 53 (28.5) 17 (18.3) 36 (38.7) 0.03
APACHE II acute physiology and chronic health evaluation, SOFA sequential organ failure assessment, CHF cardiac heart failure, ESRF end-stage renal failure, COPD
chronic obstructive pulmonary disease, VP vasopressor, VPs vasopressor start, FRLoad first fluid load with resuscitative intention, SAP systolic arterial pressure, DAP
diastolic arterial pressure, MAP mean arterial pressure, HR heart rate, PP pulse pressure, DSI diastolic shock index (HR to DAP ratio), BE base excess, SvO2 oxygen
venous saturation, Pv-aCO2 venous-to-arterial carbon dioxide difference, PvaCO2/Da-vO2 ratio venous-arterial carbon dioxide to arterial-venous oxygen differences
ratio, CVP central venous pressure, LOS-ICU intensive care unit - length of stay, LOS-Hospital hospital - length of stay, RRT renal replacement therapy
*Including only patients receiving renal replacement therapy at least for one session
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intervals, which prevents establishing precisely the num-
ber of minutes spent in hypotension in each group.
A recent randomized trial addressed the issue about
the early introduction of norepinephrine in patients
with septic shock [36]. Nevertheless, very low and
non-titrated doses of norepinephrine were used while
the idea of administering a fixed dose of fluids before
to start of the “non-blinded” vasopressor support was
maintained. Importantly, the rate of achievement of
lactate clearance after 6 h of resuscitation was ex-
tremely low and did not differ from those not receiv-
ing the study low dose of vasopressor. In contrast
with this, our patients received a MAP-targeted dose
of norepinephrine along with other resuscitation
maneuvers directed to restore tissue perfusion.





Repeated Measures ANOVA, 
inter-group di erence, p<0.001 
Repeated Measures ANOVA, 
inter-group di erence, p<0.001 
Fig. 1 Cumulative resuscitation fluids for very early- (VE-VPs) and delayed-vasopressor support (D-VPs). a Cummulative resuscitation fluids (in mL)
at the start of vasopressor, 2,4, 6, and 8 h after. b Cummulative resuscitation fluids (in mL/kg) at the start of vasopressor, 2,4, 6, and 8 h after. Very
early VPs, vasopressor support initiated before or within the next hour of the first fluid resuscitation (FRLoad). Delayed VPs, vasopressor support
initiated > 1 h of the first fluid resuscitation (FRLoad). VPs, start of vasopressor support
VE-VPs 93 80 78 78 76
D-VPs 93 70 63 57 56
Very Early VPs
Delayed VPs
Fig. 2 Cox proportional hazard model for risk of death at day 28 for very early- (VE-VPs) and delayed-vasopressor support (D-VPs). The Cox
proportional hazards model was adjusted by SOFA score at day 1, the presence of hyperlactatemia (septic shock according to Sepsis 3.0
definition), delay time of antibiotic administration, and the net fluid balance at 24 h. Very early VPs, vasopressor support initiated before or within
the next hour of the first fluid resuscitation (FRLoad). Delayed VPs, vasopressor support initiated > 1 h of the first fluid resuscitation (FRLoad). VPs,
start of vasopressor support
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was not directed by the idea of completing a prede-
termined volume of fluids in advance.
Early use of vasopressors could change the course of
hemodynamics in septic shock. A recent experimental
model of endotoxemia suggested that fluid resuscitation
might paradoxically increase vasopressor requirements
compared with an early and isolated use of VP [11]. In
the same line, our data suggests that lower doses of nor-
epinephrine could be required when VP support is intro-
duced very early, at least during the first 6 h of
resuscitation (see Additional file 1: Figure S4). Therefore,
the early onset of VP would seem to prevent the pro-
gression of circulatory dysfunction.
There are concerns about the effect of VP on splanch-
nic perfusion when hypovolemia coexists [47, 48]. Mean-
while, some experimental studies have suggested
potential benefits of early combination of vasopressors
and fluids on splanchnic blood flow [25]. Due to the
nature of our study, it is not possible to discard the con-
currence of hypovolemia. Nevertheless, fluid resuscita-
tion in both VE-VPs and D-VPs groups was guided by
using fluid responsiveness test and clinical parameters,
targeting the restoration of systemic and peripheral per-
fusion variables. In our study, the intervention consisting
of very early use of vasopressors was not associated with
an excess of acute kidney injury or increased require-
ments of acute renal replacement therapies. In addition,
most patients initially received vasopressor support
through peripheral veins for a few minutes up to a cen-
tral venous line was obtained, which was not associated
with major complications. Finally, although severe digital
ischemia cases were not observed, other side effects such
as myocardial ischemia were not systematically searched.
Our study should not be misinterpreted. It did not
evaluate whether a restrictive fluid administration, toler-
ating worse hemodynamic variables may be beneficial.
On the contrary, it evaluated the effects of the rapid
introduction of vasopressors, correcting promptly
hypotension, therefore limiting the amount of fluids
administered while otherwise achieving similar
hemodynamic goals. Indeed, fluids were administered
based on the same criteria of fluid responsiveness in
all patients. In addition, this study is not a probe for
the “1-h bundle” recently proposed [8] but rather a
hypothesis generator about the benefits of early start
of vasopressors in septic shock, emphasizing that pa-
tients of the VE-VPs group received the immediate
start of norepinephrine without completing a pre-
defined volume or resuscitation fluids.
Nevertheless, important limitations should be men-
tioned. First, the nature of this study and, therefore,
the lack of control by randomization and blinding
might limit the validity of conclusions. Admittedly, al-
though propensity scores were constructed incorpor-
ating baseline characteristics likely influencing the
decision for an early start of VP support, other non-
identifiable potential factors might not have been in-
cluded. In addition, the small sample size introduces
a risk of missing important differences at baseline
that might contribute to the observed differences in
mortality instead of early vasopressor introduction.
Second, also due to the nature of our study, it is not
possible to establish causal mechanisms leading to
differences in clinical outcomes between the groups.
Nevertheless, we speculate that the combination of
shortening of hypotension time, lower pre-vasopressor
and post-vasopressor fluid requirements, and, conse-
quently, lower net fluid accumulation could have in-
fluenced clinical outcomes. Third, acute renal failure,
acute renal replacement therapies, and digital ische-
mia were easily tracked. However, other adverse con-
sequences of the early use of vasopressors cannot be
ruled out. Fourth, we are not able to identify if the
decision of the early start of vasopressors relied on
some particular doctors, which could constitute a po-
tential factor of confusion. Finally, although the
single-center design might restrict a potential
generalization of our results, exclusions were very
limited so that this trial reflects the overall spectrum
of patients with septic shock. Furthermore, the bio-
logical plausibility of these results, the potential
physiological mechanisms of early introduction of
VPs, and the agreement with recent experimental ob-
servations deserve future research efforts.
Conclusions
A very early start of vasopressor support was associated
with a lower amount of resuscitation fluids, less fluid ac-
cumulation, and shortening of hypotension times. Very
early start of vasopressors even before completing a pre-
defined volume of fluid resuscitation seems to be a safe
intervention with potential beneficial effects on clinical
outcomes.
Table 2 Multivariate Cox regression for 28-day mortality
(propensity-matched population: n = 186)
HR 95% CI p
Net fluid balance 1.00 1.00–1.00 < 0.001
Steroids use* 4.66 1.94–11.18 0.001
Hyperlactatemia** 3.61 1.41–9.22 0.007
VE-VPs 0.31 0.17–0.57 < 0.001
SOFA Sequential Organ Failure Assessment, VE-VPs very early start of
vasopressor support
*Low-dose steroids (200–300 mg/day) used in the context of shock
**Lactate levels > 2.0 mmol/L (Third International Consensus Definitions for
Sepsis and Septic Shock—Sepsis 3.0—considers the presence of suspected
infection accompanying life-threatening organ dysfunction, use of
vasopressors, MAP < 65mmHg, and lactate levels > 2 mmol/L as septic shock)
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